Illumina SEC filings document the company’s genomics technology business, financial results, governance and capital actions. Form 8-K reports cover quarterly and annual operating results, preliminary financial updates, share repurchase authorization, management and board changes, and Regulation FD disclosures.
The filing record also includes definitive proxy materials for annual meeting matters, director elections, compensation and shareholder voting. Material-event filings document completed acquisition activity, including the purchase of SomaLogic and Sengenics aptamer-based and functional proteomics assets, along with exhibits, common-stock repurchase disclosures and other capital-structure records.
Davies Scott M reported multiple insider transaction types in a Form 4 filing for ILMN. The filing lists transactions totaling 3,290 shares at a weighted average price of $114.44 per share. Following the reported transactions, holdings were 18,707 shares.
Illumina, Inc. executive Patricia Leckman reported equity award activity. On February 12, 2026, she exercised 1,028 performance share units at an exercise price of $0, receiving the same number of Illumina common shares as a result of the company achieving at least 74% of specified performance criteria.
Following this conversion, her direct common stock holdings increased to 20,419 shares. On the same day, 424 shares of common stock were automatically disposed of at $114.44 per share to cover tax obligations tied to the award, leaving her with 19,995 shares owned directly after these transactions.
Illumina’s VP and Chief Accounting Officer, Scott D. Ericksen, reported equity award activity involving performance-based shares. On 02/12/2026, 743 performance share units were exercised at an exercise price of $0, converting into 743 shares of Illumina common stock.
According to the footnote, these shares were awarded because the company achieved at least 74% of the applicable performance criteria under a March 1, 2023 performance share grant. On the same date, 306 common shares were disposed of at $114.44 per share in a tax-withholding transaction, leaving Ericksen with direct ownership of 13,923 Illumina common shares.
Illumina, Inc. files its Form 10‑K describing a global genomics business built around sequencing and array platforms, consumables, and informatics, serving research, applied, and clinical markets. Sequencing generated 92% of 2025 revenue, with consumables the largest overall revenue component.
On June 24, 2024 Illumina completed the spin‑off of GRAIL into an independent public company and now reports a single segment, Core Illumina, while retaining about 14.5% of GRAIL’s common stock. GRAIL did not qualify as a discontinued operation and remains reflected in historical results.
The company highlights competitive and regulatory risks, including Illumina’s addition to China’s “unreliable entities list” and case‑by‑case approval requirements for exporting sequencing instruments. It reports $2,100 million of 2025 revenue from customers outside the U.S., a $738 million year‑end backlog, and ongoing heavy investment in R&D, manufacturing capacity, cybersecurity, and human capital.
Illumina director Scott Gottlieb reported an open-market purchase of company stock. On 02/09/2026, he bought 200 shares of Illumina common stock at a price of $117.81 per share. Following this transaction, he directly beneficially owned 12,723 shares of Illumina common stock.
Illumina, Inc. filed a Form 8-K to furnish a press release announcing its financial results for the fourth quarter and fiscal year ended December 28, 2025. The press release is provided as Exhibit 99.1 under Item 2.02, Results of Operations and Financial Condition, and is treated as furnished rather than filed.
The filing also lists Exhibit 104 for the cover page interactive data file embedded in the Inline XBRL document. The report is signed on behalf of Illumina by Chief Financial Officer Ankur Dhingra.
Illumina, Inc. has completed its previously announced acquisition of Standard BioTools’ aptamer-based and functional proteomics business, including SomaLogic and Sengenics group companies. The deal closed on January 30, 2026.
Illumina paid a cash purchase price of $350,000,000, subject to customary adjustments, and agreed to provide Standard BioTools with royalty streams and up to $75,000,000 in potential milestone payments tied to revenues from certain products and services. The acquired business includes KREX, Single SOMAmer, and related translational and diagnostic assays, and excludes Standard BioTools’ mass cytometry and microfluidics operations.
Illumina, Inc. reported that it has released a press release with unaudited preliminary financial results for its fourth quarter and full fiscal year ended December 28, 2025. The company furnished this update in connection with a public webcast presentation at the J.P. Morgan Healthcare Conference in San Francisco.
The webcast is available through Illumina’s Investor Relations website and will remain accessible for at least 30 days. The press release is furnished as Exhibit 99.1 to this report and is treated as furnished, not filed, which limits how it is incorporated into other regulatory documents.
Illumina, Inc. reported that its Chief Commercial Officer, Everett Cunningham, has notified the company that he will resign effective January 16, 2026. The notice was given on January 4, 2026, and the change was disclosed in connection with a current report on Form 8-K.
The company also issued a press release on January 8, 2026 describing management changes, including Cunningham’s resignation, which is included as an exhibit to the report.
Illumina’s chief legal officer reported an insider sale of common stock. On December 12, 2025, the officer sold 323 Illumina shares at a price of $136.09 per share.
Following this transaction, the officer directly holds 17,887 shares of Illumina common stock.